Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detaine… Read more
Sichuan Kelun Pharmaceutical Co Ltd (002422) - Total Liabilities
Latest total liabilities as of September 2025: CN¥11.48 Billion CNY
Based on the latest financial reports, Sichuan Kelun Pharmaceutical Co Ltd (002422) has total liabilities worth CN¥11.48 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sichuan Kelun Pharmaceutical Co Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how Sichuan Kelun Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sichuan Kelun Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Sichuan Kelun Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guangdong Haid Group Co Ltd
SHE:002311
|
China | CN¥24.28 Billion |
|
Sonoco Products Company
NYSE:SON
|
USA | $8.40 Billion |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
USA | $56.25 Million |
|
Howden Joinery Group Plc
PINK:HWDJF
|
USA | $1.16 Billion |
|
Macerich Company
NYSE:MAC
|
USA | $5.84 Billion |
|
Wex Inc
NYSE:WEX
|
USA | $13.16 Billion |
|
Lotes Co Ltd
TW:3533
|
Taiwan | NT$10.66 Billion |
|
Home BancShares Inc
NYSE:HOMB
|
USA | $18.49 Billion |
Liability Composition Analysis (2007–2024)
This chart breaks down Sichuan Kelun Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sichuan Kelun Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sichuan Kelun Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total liabilities of Sichuan Kelun Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥10.58 Billion | -21.29% |
| 2023-12-31 | CN¥13.44 Billion | -22.00% |
| 2022-12-31 | CN¥17.23 Billion | -1.03% |
| 2021-12-31 | CN¥17.41 Billion | -3.17% |
| 2020-12-31 | CN¥17.98 Billion | +2.28% |
| 2019-12-31 | CN¥17.58 Billion | +7.21% |
| 2018-12-31 | CN¥16.40 Billion | +2.44% |
| 2017-12-31 | CN¥16.01 Billion | +34.01% |
| 2016-12-31 | CN¥11.94 Billion | +4.59% |
| 2015-12-31 | CN¥11.42 Billion | +11.60% |
| 2014-12-31 | CN¥10.23 Billion | +29.15% |
| 2013-12-31 | CN¥7.92 Billion | +35.05% |
| 2012-12-31 | CN¥5.87 Billion | +131.48% |
| 2011-12-31 | CN¥2.53 Billion | +45.80% |
| 2010-12-31 | CN¥1.74 Billion | -0.90% |
| 2009-12-31 | CN¥1.75 Billion | +19.65% |
| 2008-12-31 | CN¥1.47 Billion | +33.75% |
| 2007-12-31 | CN¥1.10 Billion | -- |